Lindis Biotech has announced positive data from all three dose groups from its ongoing Catunibla phase 1 trial. The objective of developing the drug candidate is to reduce the rate of radical bladder removal – also known as cystectomy – as well as to decrease recurrence and progression rates.
The study has been testing the trifunctional anti-EPCAM/CD3 monoclonal antibody Catumaxomab and has demonstrated an excellent safety and tolerability profile in addition to preliminary efficacy. Indeed, data from all three dose levels confirmed the findings from the two lower dose levels that were announced previously. As with previous findings, Catumaxomab was well tolerated and there was no dose-limiting toxicity.
